-
EP3380523
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3380523
| EP3380523 - FGFR2 INHIBITORS ALONE OR IN COMBINATION WITH IMMUNE STIMULATING AGENTS IN CANCER TREATMENT [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 18.04.2020 Database last updated on 11.01.2025 | |
| Former | Request for examination was made Status updated on 31.08.2018 | ||
| Former | The international publication has been made Status updated on 02.06.2017 | ||
| Former | unknown Status updated on 06.01.2017 | Most recent event Tooltip | 22.11.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Five Prime Therapeutics, Inc. 111 Oyster Point Boulevard South San Francisco, CA 94080 / US | [2018/40] | Inventor(s) | 01 /
PIERCE, Kristen 111 Oyster Point Boulevard South San Francisco California 94080 / US | 02 /
POWERS, Janine 111 Oyster Point Boulevard South San Francisco California 94080 / US | 03 /
PALENCIA, Servando 111 Oyster Point Boulevard South San Francisco California 94080 / US | 04 /
SIKORSKI, Robert 111 Oyster Point Boulevard South San Francisco California 94080 / US | 05 /
GHODDUSI, Majid 111 Oyster Point Boulevard South San Francisco California 94080 / US | 06 /
KRISHNAN, Kartik 111 Oyster Point Boulevard South San Francisco California 94080 / US | [2018/40] | Representative(s) | Dörries, Hans Ulrich df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte PartG mbB Theatinerstrasse 16 80333 München / DE | [N/P] |
| Former [2018/40] | Denison, Christopher Marcus, et al Mewburn Ellis LLP City Tower 40 Basinghall Street London EC2V 5DE / GB | Application number, filing date | 16816789.8 | 22.11.2016 | [2018/40] | WO2016US63332 | Priority number, date | US201562258731P | 23.11.2015 Original published format: US 201562258731 P | US201662314174P | 28.03.2016 Original published format: US 201662314174 P | US201662379094P | 24.08.2016 Original published format: US 201662379094 P | [2018/40] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017091577 | Date: | 01.06.2017 | Language: | EN | [2017/22] | Type: | A1 Application with search report | No.: | EP3380523 | Date: | 03.10.2018 | Language: | EN | The application published by WIPO in one of the EPO official languages on 01.06.2017 takes the place of the publication of the European patent application. | [2018/40] | Search report(s) | International search report - published on: | EP | 01.06.2017 | Classification | IPC: | C07K16/28, G01N33/574 | [2018/40] | CPC: |
C07K16/2863 (EP,CN,IL,KR,RU,US);
A61K39/39558 (IL,KR,RU);
A61K39/3955 (CN);
A61K45/06 (CN);
A61P1/04 (EP,IL);
A61P1/16 (EP,IL);
A61P1/18 (EP,IL);
A61P11/00 (EP,IL);
A61P13/10 (EP,IL);
A61P13/12 (EP,IL);
A61P15/00 (EP,IL);
A61P17/00 (EP,IL);
A61P35/00 (EP,CN,IL,KR,RU);
A61P37/04 (EP,IL);
A61P43/00 (EP,IL);
C07K16/2818 (EP,CN,IL,KR,US);
C07K16/2896 (IL,KR,US);
C07K16/3015 (IL,US);
C07K16/3023 (IL,US);
C07K16/303 (IL,US);
C07K16/3038 (IL,US);
C07K16/3046 (IL,US);
C07K16/3069 (IL,US);
C07K16/3084 (EP,IL,RU,US);
G01N33/5091 (IL,KR,US);
G01N33/574 (IL,RU);
G01N33/57407 (IL,KR,US);
G01N33/57446 (IL,US);
G01N33/57492 (EP,IL,US);
A61K2039/505 (EP,CN,IL,KR,US);
A61K2039/507 (EP,CN,IL,KR,US);
A61K2039/55 (EP,IL,KR,US);
C07K2317/34 (EP,CN,IL,KR,US);
| C-Set: |
A61K39/3955, A61K2300/00 (CN)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/40] | Title | German: | FGFR2-INHIBITOREN ALLEIN ODER IN KOMBINATION MIT IMMUNSTIMULIERENDEN MITTELN IN DER KREBSBEHANDLUNG | [2018/40] | English: | FGFR2 INHIBITORS ALONE OR IN COMBINATION WITH IMMUNE STIMULATING AGENTS IN CANCER TREATMENT | [2018/40] | French: | INHIBITEURS DE FGFR2 SEULS OU EN COMBINAISON AVEC DES AGENTS DE STIMULATION IMMUNITAIRE DANS LE TRAITEMENT DU CANCER | [2018/40] | Entry into regional phase | 15.06.2018 | National basic fee paid | 15.06.2018 | Designation fee(s) paid | 15.06.2018 | Examination fee paid | Examination procedure | 15.06.2018 | Examination requested [2018/40] | 15.06.2018 | Date on which the examining division has become responsible | 25.01.2019 | Amendment by applicant (claims and/or description) | 22.04.2020 | Despatch of a communication from the examining division (Time limit: M06) | 26.11.2020 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 05.02.2021 | Reply to a communication from the examining division | 06.12.2023 | Despatch of a communication from the examining division (Time limit: M06) | 05.06.2024 | Reply to a communication from the examining division | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 05.02.2021 | Request for further processing filed | 05.02.2021 | Full payment received (date of receipt of payment) Request granted | 17.02.2021 | Decision despatched | Fees paid | Renewal fee | 15.06.2018 | Renewal fee patent year 03 | 14.11.2019 | Renewal fee patent year 04 | 13.11.2020 | Renewal fee patent year 05 | 10.11.2021 | Renewal fee patent year 06 | 22.11.2022 | Renewal fee patent year 07 | 22.11.2023 | Renewal fee patent year 08 | 21.11.2024 | Renewal fee patent year 09 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]WO2007134210 (GENENTECH INC [US], et al); | [XY]WO2008065543 (CENTELION [FR], et al); | [A]WO2012021841 (ATTOGEN INC [US], et al); | [XY]WO2012162561 (ZYNGENIA INC [US], et al); | [Y]US2013309250 (COGSWELL JOHN [US], et al); | [Y]WO2014179448 (FIVE PRIME THERAPEUTICS INC [US], et al); | [Y]WO2015017600 (FIVE PRIME THERAPEUTICS INC [US]); | [XY]US2015210769 (FREEMAN GORDON JAMES [US], et al); | [Y]WO2015116868 (CARIS MPI INC [US]); | by applicant | US4816567 | US5500362 | US5545807 | US5545806 | WO9730087 | US5821337 | WO9858964 | US5874299 | US5877397 | WO9910494 | WO9922764 | WO0061739 | US6162963 | WO0129246 | US6255458 | EP1125584 | US6300129 | WO0231140 | US2002164328 | WO03011878 | US2003115614 | US6602684 | US2003157108 | WO03085119 | WO03084570 | WO03085107 | US6673986 | US6713610 | US2004093621 | US6737056 | US2004110704 | US2004110282 | US2004109865 | US2004132140 | WO2004056312 | US6808710 | WO2004113304 | WO2005035586 | WO2005035778 | US2005123546 | WO2005053742 | US6982321 | WO2006029879 | WO2006076288 | US7087409 | WO2006105021 | WO2006122150 | US2006270045 | WO2007014123 | WO2007075598 | WO2008036653 | WO2008036642 | WO2008077546 | WO2008132601 | WO2009009116 | US7488802 | WO2009044273 | US7527791 | WO2009073620 | WO2009115665 | WO2010017198 | WO2010019570 | WO2011028683 | US7923538 | WO2011056652 | US7994290 | US8008449 | WO2011109400 | US8101723 | WO2012032433 | US8168757 | WO2012142237 | WO2012145493 | US8338569 | US8354509 | WO2013014668 | WO2013173223 | US2013324701 | US8609089 | WO2014008218 | US8686119 | US8900587 | US2015050273 | WO2015031667 |